|
|
- Toby McKinney
- 6 years ago
- Views:
Transcription
1 12 TH INTERNATIONAL WORKSHOP ON CO-INFECTION HIV & HEPATITIS BERLIN, GERMANY JUNE 2016 MEETING PROSPECTUS
2 CONTENT Introduction... 3 Workshop description... 4 Background... 4 Meeting Objectives... 4 Learning Objectives... 4 Format... 4 Unique Meeting Features... 5 Target audience... 5 Demographics... 5 Geographical Distribution... 5 Organizing Committee... 6 Scientific Committee... 8 Participants Feedback Learning Objectives... 9 Impact... 9 General Conference Experience... 9 Organization Lectures Metrics Publicity Motivation Quotes...16 Summarys
3 INTRODUCTION The HIV/Hepatitis Co-infection workshop was initiated 12 years ago to address the rising need among clinicians and researchers for a workshop specifically focusing on these very challenging patients. With the success of antiretroviral therapy, HIV infected patients were seeing improvement in longevity, only to be challenged with the dangers and complications of their additional viral infection. Depending on the country - this was either a majority, or a significant minority of the HIV patients under care. Although HIV/Hepatitis co-infection was a small part of some major HIV conferences, the field lacked a dedicated meeting on this topic. Over the years more and more educational components were added given the growing needs of clinicians to keep up with the rapid developments. The HIV/Hepatitis Co-infection workshop still remains the only focused co-infection meeting in the field. The 2016-edition will continue to focus on developments in basic science, emerging therapies and clinical management. It will emphasize translational research and best practices in the clinical management of Hepatitis and HIV co-infection. We hope this information is of interest. Please contact us if specific information is missing and we will gladly provide you with additional documentation. Kind regards, MARION PETERS, MD University of California San Francisco, CA, USA JÜRGEN ROCKSTROH, MD University of Bonn Bonn, Germany STEFAN MAUSS, MD Center for HIV and Hepatogastroenterology, Düsseldorf, Germany Chairs
4 WORKSHOP DESCRIPTION BACKGROUND Initiated 12 years ago, this annual workshop is the leading medical gathering for those involved in the clinical care of co-infected individuals. The program provides an excellent platform to exchange the medical information and new treatment results, and to discuss them with the experts active in the different disciplines (including Virology, Hepatology, Immunology, Infectious Disease and Primary Care). MEETING OBJECTIVES To gather clinicians involved in the treatment HIV and Hepatitis Co-infection in an interactive workshop setting To improve the basic knowledge of antiviral therapy and give basic guidance to healthcare professionals involved in treatment of co-infected patients To provide a platform for presentation and discussion of the latest developments in the field To map current studies and results To translate new data to treatment guidelines To educate clinicians on how to best implement current and new drugs LEARNING OBJECTIVES After participating in this activity, the participants will demonstrate the ability to optimally manage their patients with HIV/HCV co-infection and HIV/HBV co-infection, including strategies for avoiding drug-drug interactions and improving patient adherence to therapy. Strategies for avoiding drug-drug interactions so as to optimally manage patients with HIV/HDV co-infections and HIV/HBV co-infections. Strategies to improve patient adherence to therapy. Strategies to manage co-infected patients with cirrhosis and end stage liver disease. FORMAT The format of the workshop includes plenary expert presentations, discussion sessions on areas currently lacking consensus, and abstract-driven presentations. Experts in the area are invited to give state-of-the-art lectures and controversial patient cases are be discussed by expert panels. Although originally this meeting is abstract-driven, starting 2013 it was decided to emphasize the educational character of this meeting, limiting oral abstract presentations. Poster sessions remain a very important part of this workshop. To ensure the quality of accepted abstracts, all submitted abstracts go through a blind, peer-reviewed process conducted by the members of the Organizing and Scientific Committees. The below table shows the abstract submission statistics from the past four years: Total number accepted abstracts Oral presentations Poster presentations
5 UNIQUE MEETING FEATURES The International Co-infection workshop is a clinically focused workshop in which all world experts are present to share their experience and discuss their data. The cross-disciplinary sharing of information between hepatologists and infectious disease experts creates a unique opportunity to further improve the daily management of HIV and Hepatitis co-infected patients. TARGET AUDIENCE The primary target audience for the International Co-infection workshop are clinicians involved in daily care for coinfected patients. DEMOGRAPHICS Clinicians 78% 72% 72% 81% 67% Researchers 11% 9% 11% 11% 19% Post-graduate students 5% 4% 5% 3% Regulatory / Industry 4% 9% 4% 5% Nurses 7% Other 7% TOTAL number of participants GEOGRAPHICAL DISTRIBUTION Australia 2 Austria 2 Canada 13 Czech Republic 1 Finland 4 Germany 2 Greece 7 Hungary 2 India 1 Israel 1 Italy 1 Poland 1 Portugal 19 Romania 1 Saudi Arabia 1 Spain 119 Switzerland 5 Tanzania 1 The Netherlands 2 United Kingdom 59 USA 6 5
6 ORGANIZING COMMITTEE CHARLES BOUCHER, MD, PHD Erasmus Medical Center Rotterdam, the Netherlands DOUGLAS DIETERICH, MD Mount Sinai Medical Center New York, NY, USA KARINE LACOMBE, MD, PHD Hôpital Saint Antoine Paris, France MARK NELSON, MD Chelsea and Westminster Hospital London, UK MARION PETERS, MD University of California San Francisco, CA, USA MASSIMO PUOTI, MD Niguarda Cà Granda Hospital Milan, Italy 6
7 ORGANIZING COMMITTEE JÜRGEN ROCKSTROH, MD University of Bonn Bonn, Germany RUI SARMENTO E CASTRO, MD Hospital Joaquin Urbano Porto, Portugal VICENTE SORIANO, MD, PHD Hospital Carlos III Madrid, Spain JONATHAN SCHAPIRO, MD Sheba Medical Center Tel Aviv, Israel KENNETH SHERMAN, MD, PHD University of Cincinnati Cincinnati, OH, USA MARK SULKOWSKI, MD Johns Hopkins University Baltimore, MD, USA 7
8 SCIENTIFIC COMMITTEE Sanjay Bhagani...Royal Free Hospital London, United Kingdom Raffaele Bruno...University of Pavia, Italy Giampiero Carosi...University of Brescia, Italy Andy Hoepelman...UMC Utrecht, the Netherlands Andrzej Horban...Hospital for Infectious Diseases, Poland Patrick Ingiliz...Medical Center for Infectious Diseases, Germany Arthur Kim...Massachusetts General Hospital, USA Marina Klein...McGill University Health Centre, Canada Sharon Lewin...Monash University Alfred Hospital, Australia Stefan Mauss...Center for HIV and Hepatogastroenterology, Germany Marina Nuñez...Wake Forest University Health Sciences, USA Juan A. Pineda...Hospital de Valme, Spain Stanislas Pol...Hôpital Cochin, France Giuliano Rizzardini...University of Milan, Italy Dominique Salmon...Hopital Cochin, France Ulrich Spengler...University of Bonn, Germany Cristina Tural...Hospital Germans Trias i Pujol, Spain 8
9 PARTICIPANTS FEEDBACK 2015 LEARNING OBJECTIVES The following objectives have been met: Agree Neutral Disagree Not applicable Insight in optimal management of co-infected patients 95% 0% 5% 0% Knowledge on the complications of liver disease 96% 0% 4% 0% IMPACT Attendance to the meetings has changed my Agree Neutral Disagree Not applicable Thinking 81% 9% 10% 0% Behaviour 71% 19% 10% 0% Prescribing 34% 43% 9% 14% GENERAL CONFERENCE EXPERIENCE Good Average Poor Not applicable Overall event experience 96% 0% 4% 0% Opportunity of networking 78% 18% 4% 0% Content of the conference 96% 0% 4% 0% Time allocation for discussion 96% 0% 4% 0% Time allocation per presentation 96% 0% 4% 0% Agree Neutral Disagree Not applicable No commercial bias (product selling) perceived 91% 0% 9% 0% I would recommend this conference to my peers 91% 5% 4% 0% I plan to attend this conference next year 73% 18% 9% 0% 9
10 PARTICIPANTS FEEDBACK 2015 ORGANIZATION Good Average Poor Not applicable Content of electronic announcements 80% 12% 0% 8% Frequency of electronic announcements 84% 8% 0% 8% Information of conference website 88% 4% 4% 4% Online registration process 67% 8% 0% 25% Online abstract submission process 39% 0% 4% 57% Meeting venue 79% 21% 0% 0% Food & beverage 75% 25% 0% 0% Audiovisuals 96% 4% 0% 0% Onsite logistics 96% 4% 0% 0% Service level of Conference Secretariat 92% 0% 0% 8% 10
11 PARTICIPANTS FEEDBACK 2015 LECTURES THURSDAY 11 JUNE Pre-workshop Educational Course HCV - the virus G. Dusheiko, Royal Free Hospital, UK Acute hepatitis C C. Boesecke, MD, Bonn University Hospital, Germany Chronic hepatitis and HIV: implications for care J. Rockstroh, MD, University of Bonn, Germany Non hepatic complications K. Sherman, MD, PhD, University of Cincinnati, USA Treatment of HCV in HIV M. Sulkowski, MD, John Hopkins University, USA ESLD a guide for HIV physicians M. Peters, MD, University of California, USA Topic 91% 2% 1% 6% Content 89% 5% 0% 6% Performance 92% 2% 0% 6% Topic 88% 5% 2% 5% Content 92% 2% 0% 6% Performance 89% 5% 0% 6% Topic 94% 5% 1% 0% Content 97% 2% 1% 0% Performance 95% 3% 2% 0% Topic 94% 3% 3% 0% Content 95% 2% 3% 0% Performance 95% 2% 3% 0% Topic 94% 3% 3% 0% Content 95% 2% 3% 0% Performance 95% 2% 3% 0% Topic 92% 5% 3% 0% Content 93% 5% 2% 0% Performance 95% 3% 2% 0% 11
12 PARTICIPANTS FEEDBACK 2015 Session 1: The changing world of hepatitis What s new in HCV/HIV coinfection therapy M.Sulkowski, MD, John Hopkins University, USA Will DAA drugdrug interactions matter in the future D. Back, PhD, University of Liverpool, UK Viral hepatitis and pregnancy E. Nastouli, FRCPH, FRCPath, University College London Hospitals NHS Trust, UK Topic 100% 0% 0% 0% Content 100% 0% 0% 0% Performance 100% 0% 0% 0% Topic 100% 0% 0% 0% Content 100% 0% 0% 0% Performance 100% 0% 0% 0% Topic 93% 0% 0% 7% Content 65% 12% 11% 12% Performance 85% 4% 4% 7% Session 2: Money makes the world go around Cost per cure - is it worth it? D. Dieterich, MD, Mount Sinai Medical Centre, USA Towards more affordable HCV therapy A. Hill, MD, University of Liverpool, UK Topic 100% 0% 0% 0% Content 88% 4% 4% 4% Performance 96% 0% 4% 0% Topic 100% 0% 0% 0% Content 86% 0% 9% 5% Performance 100% 0% 0% 0% 12
13 PARTICIPANTS FEEDBACK 2015 FRIDAY 12 JUNE Session 3: Cost-effectiveness in hepatitis care and management ESLD and its complications M. Puoti, MD, Niguarda Ca Granda Hospital, Italy Management of HCV: pre / post transplant K. Agarwal, MD, Kings College Hospital, UK Immunology and the pathophysiology of liver disease in coinfection R. Chung, MD, Massachusetts General Hospital, USA NASH, what is it, who gets it and what are the implications for the HIV patient E. Tsotchatzis, MD, MSc, FEBTM, PhD, Health Royal Free Hospital, UK Topic 94% 0% 0% 6% Content 94% 0% 0% 6% Performance 94% 0% 0% 6% Topic 92% 0% 3% 6% Content 91% 3% 0% 6% Performance 94% 0% 0% 6% Topic 88% 0% 6% 6% Content 74% 15% 5% 6% Performance 88% 3% 3% 6% Topic 94% 0% 3% 3% Content 90% 7% 0% 3% Performance 88% 7% 2% 3% Session 4: Management of other viral hepatitis HBV - current and future treatment paradigms P. Kennedy, MD, Royal Free Hospital, UK Viral hepatitis and malignancy D. Pinato, MD, MRCP (UK) MRes, PhD, Imperial College London - Hammersmith Hospital, UK Topic 89% 4% 7% 0% Content 90% 7% 4% 0% Performance 89% 7% 4% 0% Topic 92% 0% 8% 0% Content 92% 0% 8% 0% Performance 84% 8% 8% 0% 13
14 PARTICIPANTS FEEDBACK 2015 Delta hepatitis - new approaches to therapy V. Soriano, MD, PhD, La Paz University Hospital, Spain Recreational drug use in the HIV population D. Stuart, 56 Dean Street s GUM/HIV Clinic, UK Topic 96% 0% 4% 0% Content 96% 0% 4% 0% Performance 88% 8% 4% 0% Topic 96% 0% 0% 4% Content 96% 0% 0% 4% Performance 91% 5% 0% 5% Session 5: Abstract driven presentations The impact of HIV and hepatitis B virus on hepatic stellate cell activation using a novel in vitro system K.P. Singh, Monash University, Australia European mitochondrial DNA haplogroups impact on liver fibrosis progression among HCV and HIV/HCV coinfected patients from Northwest Spain E. Poveda, Instituto de Investigación Biomédica de A Coruña (INIBIC), Spain Hepatitis C virus co-infection independently increases the risk of cardiovascular disease in HIV-positive patients V. Soriano, La Paz University Hospital, Madrid, Spain NS3 resistance-associated mutations occurring as highfrequency and low-frequency variants among treatmentnaïve patients infected with hepatitis C virus (HCV) genotype 1a A.M. Geretti, University of Liverpool, UK Real-World Data on HIV positive patients with Hepatitis C on Simeprevir and/or Sofosbuvir D. Del Bello, Mount Sinai Medical Center, USA Topic 78% 0% 14% 7% Content 85% 0% 0% 15% Topic 83% 0% 17% 0% Content 75% 0% 17% 8% Topic 92% 0% 8% 0% Content 85% 0% 15% 0% Topic 77% 8% 7% 8% Content 77% 8% 8% 7% Topic 93% 0% 0% 7% Content 93% 0% 0% 7% 14
15 METRICS 2015 ATTENTION TO THIS MEETING WAS DRAWN BY Virology Education announcement 9% Virology Education website 15% Flyer at other meetings 3% Industry invite 18% Word of mouth 23% Previous workshop: I attend every year 26% INFLUENCED TO ATTEND THIS MEETING BY Meeting objectives 24% Scientific program 49% Experience from precious edition 20% Opportunity to meet with colleagues 7% 15
16 QUOTES Good and effective interaction with experts, clinical oriented information. The invited talks on treatments and outcomes Panel discussions, talks by experts - fantastic opportunity Pre workshop - very educational, a good start Summary of EASL (update) Overall good meeting. Enjoyed the general reviews and updates on pathogenesis of liver and extrahepatic complications Always very useful contents, clinically oriented. See you next year! Excellent! 16
17 SUMMARY Since its initiation 12 years ago, the HIV/Hepatitis Co-infection workshop remains the only focused co-infection meeting in the field. The program provides an excellent platform to exchange the medical information and new treatment results, and to discuss them with the experts active in the different disciplines (including Virology, Hepatology, Immunology, Infectious Disease and Primary Care). The cross-disciplinary sharing of information between hepatologists and infectious disease experts creates a unique opportunity to further improve the daily management of HIV and Hepatitis co-infected patients. The Organizing Committee is pleased with the results of the 10 th International workshop on HIV and Hepatitis Co-infection. The workshop clearly meets a need for international interchange on this important topic. The Organizing Committee therefore looks forward to organizing the 12 th edition of the workshop and to welcoming returning and new participants in June 2016 in Berlin. 17
13TH INTERNATIONAL WORKSHOP ON CO-INFECTION HIV & HEPATITIS LISBON, PORTUGAL 24-26 MAY 2017 SPONSORSHIP REQUEST 2017 www.expertmedicalevents.com INTRODUCTION & SIGNIFICANCE BACKGROUND Support our efforts
More information11 TH INTERNATIONAL WORKSHOP ON CO-INFECTION HIV & HEPATITIS LONDON, UNITED KINGDOM 11-12 JUNE 2015 MEETING PROSPECTUS www.virology-education.com CONTENT Introduction... 3 Workshop description... 4 Background...
More informationMEETING PROSPECTUS www.virology-education.com CONTENT Introduction... 3 Workshop description... 4 Background...4 Meeting Objectives...4 Learning Objectives...4 Format...4 Unique Meeting Features...4 Target
More information10 5 TH TH WORKSHOP INTERNATIONAL WORKSHOP ON CO-INFECTION NEW ANTIVIRALS IN CLINICAL PRACTICE HIV & HEPATITIS AMSTERDAM, PARIS, FRANCE THE NETHERLANDS 12-13 JUNE 2014 4-5 DECEMBER 2015 MEETING PROSPECTUS
More informationMEETING PROSPECTUS 3 RD EUROPEAN WORKSHOP ON WORKSHOP ON HEALTHY LIVING WITH HIV.
3 RD EUROPEAN WORKSHOP ON WORKSHOP ON HEALTHY LIVING WITH HIV BARCELONA, SPAIN, TBC SEPTEMBER 2018 TBC MEETING PROSPECTUS www.hivhealthyliving.com www.expertmedicalevents.com ADVANCING HEALTH GLOBALLY
More informationINTERNATIONAL MASTERCLASS ON LIVER DISEASE IN HIV VILNIUS, LITHUANIA 18 SEPTEMBER 2019 (TBC) REQUEST FOR SUPPORT.
INTERNATIONAL MASTERCLASS ON LIVER DISEASE IN HIV VILNIUS, LITHUANIA 18 SEPTEMBER 2019 (TBC) REQUEST FOR SUPPORT INTRODUCTION Liver disease in the setting of HIV is increasingly presenting a major concern
More informationThe Academy for Clinical Debates & Controversies in Medicine C-HEP CONTROVERSIES IN THE MANAGEMENT OF VIRAL HEPATITIS BARCELONA SPAIN MAY 19-22, 2011
The Academy for Clinical Debates & Controversies in Medicine C-HEP 1 st World Congress on CONTROVERSIES IN THE MANAGEMENT OF VIRAL HEPATITIS Second ANNOUNCEMENT Last update: February 1, 2011 www.comtecmed.com/chep
More informationThe Academy for Clinical Debates & Controversies in Medicine C-HEP BARCELONA SPAIN MAY 19-22, 2011 ANNOUNCEMENT
The Academy for Clinical Debates & Controversies in Medicine C-HEP 1 st World Congress on CONTROVERSIES IN THE MANAGEMENT OF VIRAL HEPATITIS Second ANNOUNCEMENT Last update: March 9, 2011 www.comtecmed.com/chep
More informationHIV FORA: INTEGRATING SCIENCE AND CLINICAL PRACTICE EUROPEAN HIV FORUM: INTEGRASE INHIBITORS MILAN, ITALY 24 OCTOBER 2017 MEETING PROSPECTUS 2017 www.virology-education.com INTRODUCTION & SIGNIFICANCE
More informationREQUEST FOR SUPPORT 5 TH CENTRAL AND EASTERN EUROPEAN MEETING ON VIRAL HEPATITIS AND HIV BUDAPEST, HUNGARY OCTOBER 2019 (TBC)
5 TH CENTRAL AND EASTERN EUROPEAN MEETING ON VIRAL HEPATITIS AND HIV BUDAPEST, HUNGARY 10-11 OCTOBER 2019 (TBC) REQUEST FOR SUPPORT OVERVIEW INTRODUCTION The main objective of the Central and European
More informationEVALUATION REPORT
International Workshop on NASH Biomarkers 2017 5-6 May 2017 Washington, D.C., EVALUATION REPORT www.expertmedicalevents.com/nashbiomarkers EXECUTIVE SUMMARY INTRODUCTION The 2 nd International Workshop
More informationMEETING PROSPECTUS. HIV CLINICAL FORUM INTEGRASE INHIBITORS DURBAN, SOUTH AFRICA 16 July 2016
MEETING PROSPECTUS HIV CLINICAL FORUM INTEGRASE INHIBITORS DURBAN, SOUTH AFRICA 16 July 2016 VIROLOGY EDUCATION BILTSTRAAT 106 3572 BJ UTRECHT THE NETHERLANDS +31 30 230 7140 INFO@VIROLOGY-EDUCATION.COM
More informationHIV FORA: INTEGRATING SCIENCE AND CLINICAL PRACTICE EUROPEAN HIV FORUM: INTEGRASE INHIBITORS MILAN, ITALY 24 OCTOBER 2017 MEETING PROSPECTUS 2017 www.virology-education.com INTRODUCTION & SIGNIFICANCE
More information1 ST EUROPEAN. NASH Workshop BARCELONA, SPAIN 8-9 MARCH 2019 REQUEST FOR SUPPORT.
1 ST EUROPEAN NASH Workshop BARCELONA, SPAIN 8-9 MARCH 2019 REQUEST FOR SUPPORT NEEDS ASSESSMENT NEEDS ASSESSMENT Non-alcoholic fatty liver disease (NAFLD) is an emerging liver disease affecting 25 % of
More informationHepatocellular Carcinoma in HIV-infected Patients A Growing Complication of Coinfection with HCV or HBV Mon, 31 May 2010
Bronx VA Medical Center Mount Sinai School of Medicine Hepatocellular Carcinoma in HIV-infected Patients A Growing Complication of Coinfection with HCV or HBV Mon, 31 May 2010 Norbert Bräu, MD, MBA Associate
More informationINTERNATIONAL WORKSHOP ON HIV & TRANSGENDER PEOPLE MEXICO CITY, MEXICO JULY 2019 MEETING PROSPECTUS.
INTERNATIONAL WORKSHOP ON HIV & TRANSGENDER PEOPLE MEXICO CITY, MEXICO JULY 2019 MEETING PROSPECTUS INTRODUCTION Dear Colleagues, It is our pleasure to announce the organization of the first Workshop focusing
More information13th Residential Course on Clinical Pharmacology of Antiretrovirals. Turin, January 2018
13th Residential Course on Clinical Pharmacology of Antiretrovirals Turin, 17-19 January 2018 NOTES 13th Residential Course on Clinical Pharmacology of Antiretrovirals Turin, 17-19 January 2018 COURSE
More informationThe need for surveillance: How to implement it? Stephanie Popping, MD. Erasmus Medical Center Rotterdam
The need for surveillance: How to implement it? Stephanie Popping, MD. S.Popping@erasmusmc.nl Erasmus Medical Center Rotterdam Era of direct-acting antivirals HCV treatment changed incredibly DAAs are
More informationSuccessful hepatitis C treatment lowers risk of death for people with HIV and HCV co infection
Successful hepatitis C treatment lowers risk of death for people with HIV and HCV co infection Liz Highleyman Produced in collaboration with hivandhepatitis.com Published: 28 October 2015 Jump to Trends
More informationAngelos Hatzakis. 10th Paris Hepatology Conference
Angelos Hatzakis Professor of Epidemiology and Preventive Medicine Faculty of Medicine National and Kapodistrian University of Athens Co-Chair, Hepatitis B and C Public Policy Association 10th Paris Hepatology
More informationMEETING PROSPECTUS. International Workshop on NASH Biomarkers
International Workshop on NASH Biomarkers 2018 18-19 May 2018 Washington, D.C., USA MEETING PROSPECTUS www.expertmedicaleducation.com www.expertmedicalevents.com ADVANCING HEALTH GLOBALLY THROUGH INNOVATIVE
More informationIVHEM 2019 REQUEST FOR SUPPORT INTERNATIONAL VIRAL HEPATITIS ELIMINATION MEETING.
INTERNATIONAL VIRAL HEPATITIS ELIMINATION MEETING 2019 AMSTERDAM, THE NETHERLANDS 22-23 NOVEMBER 2019 REQUEST FOR SUPPORT OVERVIEW INTRODUCTION TO The 5th edition of was organized on 6-7 December 2018
More informationINTERNATIONAL WORKSHOP ON MANAGEMENT OF END STAGE LIVER DISEASE DUE TO NASH WASHINGTON DC, USA 6-7 OCTOBER 2016 MEETING PROSPECTUS www.expertmedicalevents.com www.expertmedicalevents.com INTRODUCTION NAFLD
More information9TH INTERNATIONAL WORKSHOP ON HIV&AGING EAST COAST, USA OCTOBER 2018 MEETING PROSPECTUS.
9TH INTERNATIONAL WORKSHOP ON HIV&AGING EAST COAST, OCTOBER 2018 MEETING PROSPECTUS www.virology-education.com www.expertmedicalevents.com ADVANCING HEALTH GLOBALLY THROUGH INNOVATIVE PROGRAMS DESIGNED
More informationInfluence of Baseline HCV Genotype upon Treatment Outcome of Acute HCV Infection in HIV Co-Infected Individuals
Influence of Baseline HCV Genotype upon Treatment Outcome of Acute HCV Infection in HIV Co-Infected Individuals Christoph Boesecke, Hans-Jürgen Stellbrink, Stefan Mauss, Emma Page, Mark Nelson, Sanjay
More informationINTERNATIONAL CONFERENCE ON MYELOID CELLS AND HIV ITALY 1-3 SEPTEMBER 2018 MEETING PROSPECTUS.
INTERNATIONAL CONFERENCE ON MYELOID CELLS AND HIV ITALY 1-3 SEPTEMBER 2018 MEETING PROSPECTUS ADVANCING HEALTH GLOBALLY THROUGH INNOVATIVE PROGRAMS DESIGNED FOR THE HEALTHCARE PROFESSIONAL 2 TABLE OF CONTENTS
More informationSPONSORSHIP REQUEST 2017 INTEREST HIV TREATMENT, PATHOGENESIS AND PREVENTION RESEARCH IN RESOURCE-LIMITED SETTINGS.
11 TH INTERNATIONAL WORKSHOP ON HIV TREATMENT, PATHOGENESIS AND PREVENTION RESEARCH IN RESOURCE-LIMITED SETTINGS INTEREST LILONGWE, MALAWI MAY 16-19 2017 SPONSORSHIP REQUEST 2017 www.virology-education.com
More information3 RD CENTRAL AND EASTERN EUROPEAN MEETING ON VIRAL HEPATITIS AND CO-INFECTION WITH HIV LJUBLJANA, SLOVENIA 27-28 SEPTEMBER 2017 EVALUATION REPORT www.virology-education.com EXECUTIVE SUMMARY The 3 rd edition
More informationProgram. Wednesday, 30 May
Wednesday, 30 May 9:00 Opening of the meeting 9:15 The role of the human microbiome on HIV infection Roger Paredes, MD, PhD Irsi Caixa Foundation, Barcelona, Spain Session 1 The future of the HIV epidemic
More informationRolling up HCV treatment programs for PWIDs in Ukraine
Rolling up HCV treatment programs for PWIDs in Ukraine www.aph.or g.ua Ludmila Maistat Alliance for Public Health VHPB Meeting, Highlight undeserved groups for screening, prevention and treatment of viral
More informationThe single tablet regimen of ledipasvir/sofosbuvir is efficacious and well-tolerated among people receiving opioid substitution therapy
The single tablet regimen of ledipasvir/sofosbuvir is efficacious and well-tolerated among people receiving opioid substitution therapy Reau N 1, Grebely J 2, Mauss S 3, Brown A 4, Puoti M 5, Wyles D 6,
More informationZimbra jan.klimas@ucd.ie The ISAM Newsletter has arrived From : ISAM Newsletter Sender : ISAM Newsletter Subject : The ISAM Newsletter
More informationAccess to treatment and disease burden
Access to treatment and disease burden Robert Flisiak Department of Infectious Diseases and Hepatology Medical University in Białystok, Poland Moulin de Vernègues, 27-29 August 2015 Disclosures Advisor
More informationAustralasian Professional Society on Alcohol and other Drugs, Annual Conference 2016 Sydney Australia
Efficacy and safety of ledipasvir/sofosbuvir with and without ribavirin in patients with chronic HCV genotype 1 infection receiving opioid substitution therapy: Analysis of Phase 3 ION trials J Grebely
More informationThe Role of Liver Societies in the Global Viral Hepatitis Response
The Role of Liver Societies in the Global Viral Hepatitis Response Anna S. Lok, MD Alice Lohrman Andrews Research Professor in Hepatology Director of Clinical Hepatology Assistant Dean for Clinical Research
More informationInfectious Disease Testing. ULTRA Product Line. Safety is not a Matter of Chance
Infectious Disease Testing ULTRA Product Line Safety is not a Matter of Chance ULTRA Product Line The best answer for HBV, HCV and HIV screening: a global automated solution for safe results. Monolisa
More informationCLINICAL PATHWAY TRACK AGENDA TUESDAY, AUGUST 23, 2016
CLINICAL PATHWAY TRACK AGENDA TUESDAY, AUGUST 23, 2016 MORNING PLENARY LECTURES: LIBERTY BALLROOM (M4) 9:00 9:15 AM Welcome and Introductions Conference Co-Chairs: Laura W. Cheever, MD, ScM; Michael S.
More informationSHOULD EVERYONE WITH HCV/HIV COINFECTION BE TREATED NOW?
SHOULD EVERYONE WITH HCV/HIV COINFECTION BE TREATED NOW? Kenneth E. Sherman, MD, PhD Gould Professor of Medicine Director, Division of Digestive Diseases University of Cincinnati College of Medicine Disclosures
More informationGLOBAL INVESTMENT IN HIV CURE RESEARCH AND DEVELOPMENT IN 2017 AFTER YEARS OF RAPID GROWTH FUNDING INCREASES SLOW
GLOBAL INVESTMENT IN HIV CURE RESEARCH AND DEVELOPMENT IN 2017 AFTER YEARS OF RAPID GROWTH FUNDING INCREASES SLOW TOWARDS AN CURE PEOPLE FOCUSED SCIENCE DRIVEN JULY 2018 A GLOBAL STRATEGIC APPROACH TOWARDS
More informationThe Role of Liver Societies in the Global Viral Hepatitis Response
The Role of Liver Societies in the Global Viral Hepatitis Response Anna S. Lok, MD Alice Lohrman Andrews Research Professor in Hepatology Director of Clinical Hepatology Assistant Dean for Clinical Research
More informationTreatment of Hepatitis C in HIV-Coinfected Patients. Vincent Soriano Department of Infectious Diseases Hospital Carlos III Madrid, Spain
Treatment of Hepatitis C in HIV-Coinfected Patients Vincent Soriano Department of Infectious Diseases Hospital Carlos III Madrid, Spain Estimated no. of persons infected with HIV and hepatitis viruses
More information47 th Annual Meeting AISF
47 th Annual Meeting AISF Rome, 21 February 2014 Present and future treatment strategies for patients with HCV infection: chronic hepatitis and special populations (HCV/HIV coinfection, advanced cirrhosis,
More informationHIV/hepatitis co-infection. Christoph Boesecke Department of Medicine I University Hospital Bonn Germany
HIV/hepatitis co-infection Christoph Boesecke Department of Medicine I University Hospital Bonn Germany Clinical Management and Treatment of HBV and HCV Co-infection in HIVpositive Persons Hepatitis B
More informationProfessor Vincent Soriano
Five Nations Conference on HIV and Hepatitis in partnership with Professor Vincent Soriano Hospital Carlos III, Madrid, Spain Professor Vincent Soriano in partnership with Hospital Carlos III, Madrid,
More informationRegistration for INTEREST 2019 is now open!
INTEREST - 13th International Conference on HIV Treatment, Pathogenesis, and Prevention Research in Resource-Limited Settings 14-17 May 2019, Accra, Ghana The PREMIER scientific platform for researchers
More informationProfessor Norbert Bräu
Sixth Annual BHIVA Conference for the Management of HIV/Hepatitis Co-Infection in collaboration with BASL and BVHG Professor Norbert Bräu James J Peters VA Medical Center, New York, USA COMPETING INTEREST
More informationRecent data in. treatment of acute hepatitis C. Christoph Boesecke Department of Medicine I Bonn University Hospital Bonn, Germany
Recent data in treatment of acute hepatitis C Christoph Boesecke Department of Medicine I Bonn University Hospital Bonn, Germany Conflict of Interest Honoraria for lectures and/or consultancies from abbvie,
More informationUnited Kingdom National External Quality Assessment Service for Microbiology [Established 1971]
United Kingdom National External Quality Assessment Service for Microbiology [Established 97] UK NEQAS covers Andrology Chemistry Genetics Haematology Histopathology Immunology Leucocyte Immunophenotyping
More informationESPACOMP SCIENTIFIC MEETING PROGRAM
ESPACOMP SCIENTIFIC MEETING PROGRAM Meeting venue Altis Grand Hotel Rua Castilho, 11 1269-072 Lisboa Portugal The program is being updated continuously upon confirmation of the speakers THURSDAY 17 NOVEMBER
More informationunder the aegis of cover picture: Chiostro d Onore University of Milan
under the aegis of cover picture: Chiostro d Onore University of Milan Milan. 2,3 July 2012 Palazzo Visconti MEETING AIM In the last year the therapeutic scenario of chronic hepatitis C has been subverted
More informationWCPT COUNTRY PROFILE December 2017 HUNGARY
WCPT COUNTRY PROFILE December 2017 HUNGARY HUNGARY NUMBERS WCPT Members Practising physical therapists 727 Total number of physical therapist members in your member organisation 4,000 Total number of practising
More informationCuring Hepatitis C: Current And Future Options For Treatment By Gregory T. Everson, Gene Schiff READ ONLINE
Curing Hepatitis C: Current And Future Options For Treatment By Gregory T. Everson, Gene Schiff READ ONLINE AASLD president will discuss current hepatitis B treatment options, to hepatitis C research,
More informationcoinfected patients predicts HBsAg clearance during long term exposure to tenofovir
Measurement of serum HBsAg in HIV/HBV coinfected patients predicts HBsAg clearance during long term exposure to tenofovir Zulema Plaza 1, Antonio Aguilera 2, Alvaro Mena 3, Luz Martín-Carbonero 1, Eugenia
More informationGlobal Patient Survey. Country-Specific Report Belgium
Global Patient Survey Country-Specific Report Belgium HCV Quest Country-Specific Report ABOUT HCV QUEST The biggest barrier I have faced in the fight against viral hepatitis is... no recognition, lack
More informationWCPT COUNTRY PROFILE December 2017 SWEDEN
WCPT COUNTRY PROFILE December 2017 SWEDEN SWEDEN NUMBERS WCPT Members Practising physical therapists 11,043 Total number of physical therapist members in your member organisation 17,906 Total number of
More informationHepatitis C Policy Discussion
Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35 Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119
More informationPRELIMINARY RYAN WHITE HIV/AIDS PROGRAM CLINICAL CARE CONFERENCE AGENDA
PRELIMINARY RYAN WHITE HIV/AIDS PROGRAM CLINICAL CARE CONFERENCE AGENDA 9:00 9:15 AM Welcome and Introductions TUESDAY, DECEMBER 15, 2015 9:00 AM 5:05 PM 9:15 9:45 AM Update on the Ryan White HIV/AIDS
More informationWCPT COUNTRY PROFILE December 2017 SERBIA
WCPT COUNTRY PROFILE December 2017 SERBIA SERBIA NUMBERS WCPT Members Practising physical therapists 622 Total number of physical therapist members in your member organisation 3,323 Total number of practising
More informationCURING HEPATITIS C IN GENERAL PRACTICE: THE FIRST 60 DAYS
CURING HEPATITIS C IN GENERAL PRACTICE: THE FIRST 60 DAYS Baker D 1,2, McMurchie M 1, Rodgers C 1, Farr V 1, Williams M 1 1 East Sydney Doctors, 2 Australasian Society for HIV Medicine 1 Disclosures Advisory
More informationGlecaprevir-Pibrentasvir in HCV GT 1 or 4 & Prior DAA Treatment MAGELLAN-1 (Part 2)
Phase 3 Treatment-Experienced in HCV GT 1 or 4 & Prior DAA Treatment MAGELLAN-1 (Part 2) in HCV GT 1 or 4 & Prior DAA Treatment MAGELLAN-1 (Part 2): Study Features MAGELLAN-1 (Part 2) Trial Design: Randomized,
More informationJuly 5 & 6, 2018, Paris SCIENTIFIC PROGRAM
www.paris-nash.org Dear Colleagues, We are delighted to announce the 4th Paris NASH Meeting to be held on July 5-6 th 2018. This international academic meeting is aimed to do a deep-dive into many aspects
More informationLink and Lead A look in the future and the role of transplant coordinators.
TRANSPLANTATION LEARNING JOURNEY Munich, Germany 6-10 2018 Second announcement 6-7 10 th ELITA 6-7 VCA 7 3 rd ETAHP 7-8 27 th 27 th Congress 3 rd Congress & Workshops Workshops 8 9-10 3 rd 9-10 Link and
More informationBioPlex 2200 Infectious Disease Panels
BioPlex 2200 System BioPlex 2200 Infectious Disease Panels An Expanding Multiplexed Assay Menu Lyme HIV Ag-Ab MMV IgM Syphilis Total & RPR MMRV EBV HSV-1 & HSV-2 EBV IgM ToRC IgM ToRC Leading the way with
More informationOlysio Pegasys Ribavirin
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.01.28 Subject: Olysio Pegasys Ribavirin Page: 1 of 8 Last Review Date: December 18, 2017 Olysio Pegasys
More informationHepatitis C reinfection after sustained virological response in HIV/HCV co-infected patients
Hepatitis C reinfection after sustained virological response in HIV/HCV co-infected patients Fábio Videira Santos, Joana Fragoso, Ana Cipriano, Miguel Araújo Abreu, Olga Vasconcelos, Ana Aboim Horta, Ana
More information8 th Congress of ECCO
European Crohn s and Colitis Organisation Vienna Austria 8 th Congress of ECCO Austria Center Vienna February 14-16, 2013 The major educational event in the field of Inflammatory Bowel Diseases in Europe
More informationClinical Evidence in the Daily Work of an Anthroposophic Hospital Dr. med. Harald Matthes, Medical Director, Havelhöhe Hospital in Berlin
Programme Venue: Time: Chair: Presentations: Members Salon, European Parliament 8:00 9:30 am Marian Harkin MEP Research Evidence in Homeopathy: Overview of published clinical investigations Robert Mathie
More informationUpdate on Real-World Experience With HARVONI
Update on Real-World Experience With A RESOURCE FOR PAYERS This information is intended for payers only. The HCV-TARGET and TRIO studies were supported by Gilead Sciences, Inc. Real-world experience data
More informationVicente Soriano Department of Infectious Diseases
Predictors of Response to Hepatitis C Therapy Vicente Soriano Department of Infectious Diseases Hospital Carlos III, Madrid, Spain Diagnosis Therapy IL28B alleles Non-invasive liver fibrosis methods Viral
More information7th International Symposium on Hepatitis Care in Substance Users
7th International Symposium on Hepatitis Care in Substance Users The Abstract Guidelines must be followed as closely as possible in order for your presentation to be considered. Please ensure that the
More informationUpdate on public hearing
Update on public hearing PCWP/HCPWP joint meeting Presented by Juan Garcia Burgos on 0 September 017 Head of Public Engagement Department An agency of the European Union A public hearing provides An opportunity
More information508 the number of suicide deaths in deaths per 100,000 people was the suicide rate in Suicide deaths in 2013 by gender
An overview of suicide statistics This document summarises information about suicide deaths in New Zealand covering up to 13. It does not attempt to explain causes of suicidal behaviour or causes of changes
More informationMEETING PROSPECTUS CHALLENGES & SOLUTIONS INTERNATIONAL WORKSHOP ON HIV ADOLESCENCE CAPE TOWN, SOUTH AFRICA OCTOBER 2018
INTERNATIONAL WORKSHOP ON HIV ADOLESCENCE CHALLENGES & SOLUTIONS CAPE TOWN, SOUTH AFRICA 10-12 OCTOBER 2018 MEETING PROSPECTUS WELCOME Dear Colleague, We are proud to announce the 2nd International Workshop
More informationAllied Health: Sustainable Integrated Health Care for all Australians
Allied Health: Sustainable Integrated Health Care for all Australians Catherine Turnbull Chief Allied and Scientific Health Advisor SA Health Presentation to Indigenous Allied Health Australia Conference,
More informationCross Border Genetic Testing for Rare Diseases
Cross Border Genetic Testing for Rare Diseases EUCERD Joint Action WP8 Helena Kääriäinen National Institute for Health an Welfare, Helsinki, Finland Starting point Possibilities and demand for genetic
More informationESSO Advanced Course on Primary Liver Tumours
ESSO Advanced Course on Primary Liver Tumours 24-25 April 2014 LIVERPOOL (UK) Endorsed by ESSO Advanced Course on Primary Liver Tumours Chair Hassan Malik, University Hospital Aintree NHS Trust, Liverpool,
More informationCurrent levels and recent trends in health inequalities in the EU: Updates from the EU Report
Current levels and recent trends in health inequalities in the EU: Updates from the EU Report Anne Scott London Health Observatory Expert Working Group on Social Determinants and Health Inequalities Luxembourg,
More informationTable Of Content. The European Influenza Surveillance Scheme... 2 Summary... 3 Coordinator, Leader contact and partners Outputs...
Table Of Content The European Influenza Surveillance Scheme... 2 Summary... 3 Coordinator, Leader contact and partners... 6 Institut Pasteur... 6 Health Division... 6 Nphs Communicable Disease Surveillance
More informationReport on the 3rd International HIV/Viral Hepatitis Co-Infection Meeting
Report on the 3rd International HIV/Viral Hepatitis Co-Infection Meeting HIV/Viral Hepatitis: Improving Diagnosis, Antiviral Therapy and Access Tongai Maponga, Rachel Matteau Matsha 22 July 2016 At present,
More informationGlobal EHS Resource Center
Global EHS Resource Center Understand environmental and workplace safety requirements that affect your global operations. 800.372.1033 bna.com/gelw Global EHS Resource Center This comprehensive research
More informationDigestive & Metabolic Diseases
4 th World Congress on Digestive & Metabolic Diseases October 29-30, 2018 San Francisco, California, USA Invitation Dear Attendees, We are glad to announce the 4 th World Congress on Digestive & Metabolic
More informationLiver stiffness predicts liver related events and mortality in HIV/HCV coinfected patients
Liver stiffness predicts liver related events and mortality in HIV/HCV coinfected patients José Vicente Fernández-Montero, Pablo Barreiro, Eugenia Vispo, Pablo Labarga, Francisco Blanco, Fernanda Rick,
More informationHCV reinfection in HCV/HIV coinfected patients treated for VHC in AIDS Center Prague
HCV reinfection in HCV/HIV coinfected patients treated for VHC in AIDS Center Prague Viktor ASTER, MD, PhD Department of Infectious and Tropical Diseases, Hospital Bulovka, First Faculty of Medicine, Charles
More informationProfessor Mark Nelson. Chelsea and Westminster Hospital, London, UK
Professor Mark Nelson Chelsea and Westminster Hospital, London, UK Treatment should be prioritized Treatment Indicated All naive and experienced pts with liver disease Prioritized Pts with fibrosis (F3)
More informationWorld Connections Committee (WCC) Report
World Connections Committee (WCC) Report 06 Co-Dependents Anonymous Service Conference Countries Where CoDA Exists This report reflects the World Connections Committee (WCC) support of the growth and development
More informationHepatitis C Policy Discussion
Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35 Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119
More informationEvaluation Report. Australian HIV Antiretroviral Guidelines Session. Australasian HIV/AIDS Conference Thursday 18 October 2012 Melbourne
Evaluation Report Australian HIV Antiretroviral Guidelines Session Australasian HIV/AIDS Conference Thursday 18 October 2012 Melbourne 1 Table of Contents Background to the Antiretroviral Guidelines Conference
More information12+ Interactive Sessions. 5+ Workshops. 5+ Keynote Lectures. 20+ Exhibitors. Control and Prevention of HIV/AIDS, STDs & STIs. 50+ Plenary Lectures
6 th World Congress on Control and Prevention of HIV/AIDS, STDs & STIs conferenceseries.com October 29-30, 2018 Valencia, Spain Dear Attendees, Invitation We are glad to announce the 6 th World Congress
More informationNewsletter. August 7, Visit
Share: Tweet Newsletter August 7, 2013 Jump to a Topic: Upcoming Events Funding Opportunities Conferences and Meetings Announcements Check out our new website! We are excited to announce the launching
More informationPROMOTION AND PROTECTION OF ALL HUMAN RIGHTS, CIVIL, POLITICAL, ECONOMIC, SOCIAL AND CULTURAL RIGHTS, INCLUDING THE RIGHT TO DEVELOPMENT
UNITED NATIONS A General Assembly Distr. LIMITED A/HRC/11/L.16 16 June 2009 Original: ENGLISH HUMAN RIGHTS COUNCIL Eleventh session Agenda item 3 PROMOTION AND PROTECTION OF ALL HUMAN RIGHTS, CIVIL, POLITICAL,
More informationBACTERIAL, VIRAL AND INFECTIOUS DISEASES
15+ Interactive Sessions 10+ Keynote Lectures 40+ Scientific Sessions 3+ Workshops 30+ Posters B2B Meetings BACTERIAL DISEASES 2018 Annual Conference on BACTERIAL, VIRAL AND INFECTIOUS DISEASES August
More informationJoint Programming in Neurodegenerative Disease Research (JPND)
Joint Programming in Neurodegenerative Disease Research (JPND) Building Alliances and Collaborations Prof. Philippe Amouyel, MD, PhD JPND Chair France Disclosure CEO of Fondation Plan Alzheimer Conference
More information